New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
07:23 EDTOVAS, CAH, ABT, AUXL, BAYRY, UHS, BLUE, ANAC, CYH, ALXNDeutsche Bank to hold a conference
39th Annual Healthcare Conference is being held in Boston on May 7-8 with webcasted company presentations to begin on May 8 at 8 am; not all company presentations may be webcasted. Webcast Link
News For OVAS;CYH;ANAC;BLUE;UHS;BAYRY;AUXL;ABT;CAH;ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 10, 2014
05:50 EDTAUXLEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTAUXLAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.
October 9, 2014
10:41 EDTALXNHigh option volume stocks
Subscribe for More Information
09:20 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTAUXLEndo says its not in position to give FY15
Subscribe for More Information
08:49 EDTAUXLEndo sees low-double digit revenue growth with Auxilium portfolio
Subscribe for More Information
08:37 EDTAUXLEndo expects Auxilium acquisition immediately accretive post close
Endo (ENDP) says the deal will provided expected annual run rate synergies of up to $175M by the first year after closing versus Auxilium's (AUXL trailing 12-month actuals as of June 30. Says synergies include Auxilium's $75M reduction in annual operating expenses previously announced. Says the deal is expected to "significantly'" enhance Endo's branded pharmaceutical business with the addition of Auxilium's men's health products and development portfolio. Says the agreement is designed to "accelerate growth" and maximize value of Auxilium's products by leveraging strengths of combined company. Says combined company will be "well positioned" to drive organic growth for branded pharmaceutical business. Says deal creates a "strong" margin profile and an enhanced near-and long-term revenue growth profile. Comments taken from the company's slide presentation regarding its combination with Auxilium.
07:49 EDTAUXLEndo and Auxilium host a joint conference call
Subscribe for More Information
07:30 EDTAUXLQLT Inc. says re-engaging assessment of options after Auxilium deal ended
Subscribe for More Information
06:52 EDTAUXLQLT Inc. merger with Auxilium terminated for superior proposal from Endo
Subscribe for More Information
06:36 EDTALXNAlexion appoints new chairman and creates Lead Independent Director position
Alexion has appointed Leonard Bell, M.D. as Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as CEO. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby has been a Director of Alexion since September 1999. Both of these appointments follow the passing of Max Link, Ph.D., who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the company’s inception in 1992.
06:32 EDTAUXLEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Endo (ENDP) and Auxilium Pharmaceuticals (AUXL) announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. The boards of both companies have unanimously approved the transaction, which is valued at $2.6B, including the repayment and assumption of debt. The transaction will include an election mechanism for Auxilium stockholders to elect cash and stock, all-stock or all-cash consideration, subject to proration in accordance with the terms of the definitive agreement. The per share consideration represents a premium of 55% to Auxilium's closing price on September 16, the day Endo made public its proposal for Auxilium. Subject to aggregate cash and equity consideration limits, Auxilium stockholders may elect one of three options with respect to transaction consideration: 100% equity which equates to 0.488 Endo shares per Auxilium share, 100% cash which equates to $33.25 per Auxilium share or a standard election of an equal mix of $16.625 in cash and 0.244 Endo shares per Auxilium share. The total cash consideration will not exceed 50% of the total equity value and the equity consideration will not exceed 75% of the total equity value. The transaction is expected to close in 1H15 and is subject to the approval of Auxilium's stockholders, regulatory approval in the U.S. and certain other jurisdictions, and other customary closing conditions.
06:31 EDTAUXLEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Subscribe for More Information
October 8, 2014
16:02 EDTANACAnacor files $70M of convertible senior notes due 2021
Subscribe for More Information
10:00 EDTOVASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:53 EDTOVASOvaScience downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
08:33 EDTCAHCardinal Health and Ohio State University complete $13M medical imaging facility
Cardinal Health , the Ohio State University and State of Ohio Third Frontier Commission have completed a five-year-long project to create a new, $13M molecular imaging pharmaceuticals center. The 27,000-square-foot facility will research and produce specialized pharmaceuticals called "imaging agents," which are injected into the body and seek out particular cellular functions that are indicative of specific disease processes. The new center supports more than 80 employees.
October 7, 2014
07:24 EDTBLUEAlliance for Regenerative Medicine
Subscribe for More Information
07:16 EDTBLUEBiotech Industry Organization to hold a forum
Subscribe for More Information
06:03 EDTCYH, UHSCMS readmission penalties increase in 2015, says Wells Fargo
Wells Fargo says CMS released the final 2015 IPPS payment penalties for hospital readmissions, with incremental earnings Impact of down 0.2% to down 1.9% at for-profit hospitals. The firm estimates Community Health Systems (CYH) and Tenet Health (THC) will see the largest incremental reimbursement reduction in 2015, equal to down 1.9% and down 1.4%, respectively. It notes 2015 is the third year of hospital readmission penalties with a maximum penalty of 3%, up from 2% in 2014 and 1% in 2013. Wells has Outperform ratings on Community Health and HCA Holdings (HCA), and Market Perform ratings on LifePoint Hospitals (LPNT), Tenet and Universal Health (UHS).
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use